Posts filtered by tags: Vertex Pharmaceuticals[x]


 

Bio Roundup: Generic Drugs Graft, ASCO Ahead, ElevateBio Rises & More

Generic drugs are supposed to give consumers more choices and a counterweight to more costly branded medications. During his tenure as FDA commissioner, Scott Gottlieb often spoke about generics as a market force that could help tame climbing drug prices. But such tools only work when companies play fair.A lawsuit is now claiming that many top generic drug makers routinely conspired to avoid competition. In a more than filed in federal court in Connecticut, 44 states allege that 18 generic dr...
Tags: Deals, Startups, Lawsuit, Breast Cancer, Drugs, Cancer, Trends, Investing, Hypertension, Connecticut, Venture Capital, Private Equity, Fda, National, Biotech, Cystic Fibrosis


Vertex Continues Plan to Diversify, Strikes a $70M Pact With Kymera

Vertex Pharmaceuticals is best known for its cystic fibrosis franchise. But over the past several years Vertex has been making inroads elsewhere, and a deal it is announcing this morning continues that strategy.Vertex (NASDAQ: VRTX), of Boston, will pay privately held startup Kymera Therapeutics $70 million to form an alliance to develop a group of drugs for “serious specialty diseases.” Vertex won’t say which ones, but beyond cystic fibrosis (CF), where it has three FDA-approved drugs that gen...
Tags: Deals, Startups, Boston, Trends, Vc, Fda, GlaxoSmithKline, Biotech, Pain, Cystic Fibrosis, Life Sciences, CRISPR Therapeutics, Vertex, Merck KGaA, Hepatitis C, Vertex Pharmaceuticals




Bio Roundup: Gottlieb’s Goodbye, AACR Recap, Migraine Drug Fight & More

Scott Gottlieb’s last day as FDA commissioner is today. His resignation announcement last month surprised some, given the earlier denials about leaving. But after two years of commuting between Connecticut, where his family remained, and the FDA’s Maryland headquarters, he decided to step down from the agency.What will Gottlieb’s legacy be? His efforts to curb teen vaping comes to mind. Or maybe it’s regulation. While Gottlieb remained mindful of the FDA’s oversight role, he also tried to strea...
Tags: Deals, Startups, Maryland, Breast Cancer, Trends, Investing, Lung Cancer, Connecticut, Cigna, Venture Capital, Fda, National, Novartis, Pfizer, Biotech, Insulin


Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More

In the biotech investment and research communities this week, much of the attention was turned to Europe.Munich, Germany, hosted the annual conference of the European Society for Medical Oncology, where cancer drug developers unveiled the latest clinical data for experimental immunotherapies and drugs that treat the disease based on a tumor’s genetic signature. Also this week, the Clinical Trials on Alzheimer’s Disease conference took place in Barcelona, Spain. As with another Alzheimer’s meeti...
Tags: Startups, Drugs, Cancer, Trends, Investing, Alzheimer's Disease, Astrazeneca, Medicare, Fda, National, Pfizer, Abbvie, Biotech, Bain Capital, Stanford University, Cystic Fibrosis


Genomics raises £25m as it announces deal with US pharma giant

Oxford biotech Genomics has raised £25m from investors and announced a collaboration with US pharmaceuticals giant Vertex that might eventually be worth tens of millions of pounds for the small UK genetics company. Investors in this latest round of funding, which brings the total raised by the company so far to £36m, include Woodford Investment Management, IP Group, Invesco Perpetual, Oxford Sciences Innovation and Vertex Pharmaceuticals, which invested £10.5m. Genomics was founded in 2014 by fo...
Tags: UK, Science, US, Genomics, GlaxoSmithKline, Amgen, Donnelly, Biogen, Vertex, Vertex Pharmaceuticals, Peter Donnelly, Vertex Genomics, Oxford biotech Genomics


Cystic fibrosis boy, 8, urges firm to lower Orkambi drug price

Luis Walker, 8, wrote to Vertex Pharmaceuticals saying Orkambi would make him "feel much better".
Tags: News, Vertex Pharmaceuticals, Orkambi, Luis Walker


Bio Roundup: Medicare Drug Prices, FDA Moves, Gene Therapy News & More

Two imminent FDA rulings on two separate drugs aren’t just noteworthy for the patients they’ll help, but the long and winding road their developers have taken to get to this point.First is Alnylam Pharmaceuticals, which has spent 16 years and over $2 billion to try to bring an unproven form of medicine, RNA interference (RNAi), to market. A positive FDA decision, which could come by Saturday, would mark RNAi as a bona fide drug-making method, and Alnylam as its standard-bearer.Then there’s Amic...
Tags: Deals, Trends, Gout, Fda, National, Roundups, Cystic Fibrosis, Life Sciences, Clinical Trials, Medicare Advantage, Chris Collins, Samumed, Regeneron Pharmaceuticals, Gene Therapy, BioMarin Pharmaceutical, Alnylam


SQZ Biotech Adds $72M as Cell Therapy Investment Keeps Burning Hot

SQZ Biotechnologies has landed its largest venture capital round yet: a $72 million Series C financing that the Watertown, MA-based company hopes can bring some of its experimental cell therapies into the clinic.SQZ has a technology that is able to squeeze cells (hence the company’s name) without killing them, enough to allow their membranes to open and allow proteins and other materials to enter. The biotech plans to use the money to continue its development of therapies for solid tumors and a...
Tags: Deals, Startups, Boston, Cancer, Trends, Mit, Autoimmune, Harvard University, Novartis, Immunotherapy, Life Sciences, Polaris Partners, Celgene, Roche, Watertown, Justin Taylor


Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More

For the next five days, the oncology community’s attention will focus on Chicago. The Windy City is the home for the American Society of Clinical Oncology’s annual meeting, and it kicks off today. Many ASCO attendees will zero in on potential cancer drug combinations. They’re seen as the key to expanding the reach of caner immunotherapy, which still works on just a small fraction of patients. Among other news, expect a post-mortem analysis of a once-promising immunotherapy combination tha...
Tags: Deals, Startups, Cancer, Trends, Investing, Food And Drug Administration, Fda, National, Biotech, Roseanne Barr, Medicaid, Life Sciences, Clinical Trials, ASCO, American Society of Clinical Oncology, Roche




5 Things You'll Want to Know From Vertex Pharmaceuticals' Q1 Conference Call

What the biotech's management had to say about what's next for Vertex.
Tags: Finance, Article, FBN, Vertex Pharmaceuticals, Motley Fool, Fbn/markets, Fox-business/markets, 2f1af626-22af-5f9e-aa82-aac9a12eded6


Edelman Health Pro Kym White Joins Vertex

Kym White, global chair of Edelman's healthcare sector, will join Vertex Pharmaceuticals on May 21. [[ This is a content summary only. Visit my website for full links, other content, and more! ]] [Author: [email protected] (Kevin McCauley)]
Tags: Pr, Edelman, Vertex Pharmaceuticals, Kevin McCauley, Edelman Health Pro Kym White Joins Vertex, Kym White


Bio Roundup: Meldonium Slip, Kratom Crackdown, Zinc Fingers & More

The 2018 Winter Olympics will end soon, and we did not skate through these games without a performance-enhancing drug allegation rearing its ugly head. This time, the drug in question was meldonium (Mildronate), a product widely available over the counter in Russia and some Eastern European countries. Though Latvian pharmaceutical company Grindeks markets meldonium for heart conditions, the drug also reportedly boosts stamina and endurance. Meldonium is not approved by the FDA for any use...
Tags: Deals, Startups, Russia, Cancer, Trends, Investing, Merck, Food And Drug Administration, Affordable Care Act, Astrazeneca, Fda, National, Parkinson's Disease, Immunotherapy, Abbvie, Biotech


Bio Roundup: Wilson’s Warning, Amazon’s Health Biz, Moderna Cash & More

The State of the Union address was…. long. At one hour and 20 minutes, President Trump fell about 9 minutes shy of the high mark. But those who stayed tuned in heard comments about several health policy matters. The President credited the FDA for a record number of generic drug approvals in 2017, which PwC notes is part of a trend that began three years ago. President Trump also said he supported “right to try,” allowing terminally ill patients try experimental drugs. The FDA’s expanded a...
Tags: Amazon, Deals, Startups, Cdc, Cancer, Trends, Investing, It, Food And Drug Administration, Berkshire Hathaway, Fda, National, University of Pennsylvania, Novartis, Parkinson's Disease, Vaccine


AmorChem collects $44.2 mln for second fund

Montreal-based AmorChem, a life sciences venture firm, has raised $44.2 million for its second fund. AmorChem II will focus on backing “promising” life science projects originating from Québec-based universities and research centers. The fund’s limited partners include the Québec government, Fonds de solidarité FTQ and Merck. PRESS RELEASE MONTRÉAL–(BUSINESS WIRE)–AmorChem II Ventures inc. is pleased to announce the launch of AmorChem II Fund L.P. (AmorChem II), a life sciences venture capital f...
Tags: Trends, Merck, Canada, Healthcare, Funds, Montreal, Quebec, Merck Co, Dominique Anglade, Vertex Pharmaceuticals, Carlos Leitao, Investissement Quebec, McCarthy Tétrault LLP, Blake Cassels Graydon LLP, Elizabeth Douville, SpecificiT Pharma


Gilman’s Next CEO Trick: Taming CAR-T Cells With Obsidian

Genetically modified medicine is here. Two CAR-T therapies, made from a patient’s living T cells, are on the market in the U.S., and many more are in various stages of clinical testing. As remarkable as they might seem, however, these medicines are still fairly crude, with no way to control them once inside a patient’s body. But a host of academics and industry researchers want to add controls to cell therapies and broaden their use. A startup called Obsidian Therapeutics is the latest to...
Tags: Deals, Startups, Boston, Trends, Vc, Harvard University, Novartis, Biotech, Stanford University, Life Sciences, Amgen, Gilead Sciences, Intrexon, Gilman, Takeda, Alexandria Real Estate Equities


Vertex Pharmaceuticals: The Gilead Sciences of Cystic Fibrosis?

In only a year, Vertex Pharmaceuticals (NASDAQ: VRTX) has grown from a market cap of around $20 billion to knocking on the door of a $40 billion market cap. The biotech isn't finished growing. Wall Street analysts project Vertex will increase earnings by nearly 70% annually over the next few years. If the biotech comes anywhere close to that level of growth, Vertex's market cap will move even higher.Interestingly, Vertex COO Ian Smith said at the Leerink conference in New York on Wednesday tha...
Tags: New York, Finance, Health Care, Gilead Sciences, Kite, Gilead, Ian Smith, Vertex, Vertex Pharmaceuticals, Vertex Pharmaceuticals NASDAQ, Getty Images Continue, Gild, Leerink, Gilead Sciences NASDAQ, VRTX, Keith Speights


2 Views on Vertex Pharmaceuticals Stock: Short Term vs. Long Term

There's a lot for investors to really like about Vertex Pharmaceuticals (NASDAQ: VRTX) . The company reached profitability earlier this year. It has reported a string of positive clinical results for its cystic fibrosis drugs. And, oh yes, the stock has more than doubled so far in 2017.Chief Commercial Officer Stuart Arbuckle answered questions at the Morgan Stanley healthcare conference on Monday, and his comments highlighted the two totally different ways investors should be looking at Vertex...
Tags: Finance, Health Care, Morgan Stanley, Vertex Pharmaceuticals, Vertex Pharmaceuticals NASDAQ, Getty Images Continue, VRTX, Keith Speights, GLPG, CRSP, 2a5a4d62-9728-11e7-a2dc-0050569d4be0, Stuart Arbuckle, Vertex Here


Vertex Pharmaceuticals vs. Regeneron Pharmaceuticals: Which Company Reported Better Earnings

Vertex Pharmaceuticals (NASDAQ: VRTX) and Regeneron Pharmaceuticals (NASDAQ: REGN) are two big-cap biotech stocks, and each recently reported second-quarter financial results that were better than analysts were expecting. The two companies, however, target very different disease indications. Vertex Pharmaceuticals is reshaping how doctors treat the life-threatening disease cystic fibrosis, while Regeneron Pharmaceuticals markets drugs used to treat vision loss, high blood cholesterol, and ec...
Tags: Finance, Health Care, Todd Campbell, Regeneron Pharmaceuticals, SNY, Vertex Pharmaceuticals, Vertex Pharmaceuticals NASDAQ, Getty Images Continue, VRTX, REGN, Regeneron Pharmaceuticals NASDAQ, BAYRY, 033c0ca4-791c-11e7-8eda-0050569d32b9


US stocks keep rising as health care companies lead the way

NEW YORK (AP) " U.S. stocks are rising Wednesday morning as gains in health care and media companies put major indexes on track to set more records. Drugmaker Vertex Pharmaceuticals is surging on positive results from potential treatments... [Author: [email protected]]
Tags: Business, New York, US, Vertex Pharmaceuticals


Markets Right Now: US stocks open higher

NEW YORK (AP) " The latest on developments in financial markets (All times local):9:35 a.m.Stocks are rising further in morning trading as health care companies, banks and consumer companies all gain ground.Vertex Pharmaceuticals... [Author: [email protected]]
Tags: Business, New York, US, Vertex Pharmaceuticals


Vertex Pharmaceuticals Stock Is Soaring: Here's Why It's Still Not Too Late to Buy

Just last week, I wrote why you'd be smart to buy Vertex Pharmaceuticals (NASDAQ: VRTX) stock. At that time, Vertex was up around 70% for the year. My argument then was that the stock was still undervalued even with a forward earnings multiple of 41 because of its growth prospects, particularly with its three-drug combination treatments for cystic fibrosis (CF). Vertex announced results from phase 1 and phase 2 studies of three different triple-combination CF therapies on Tuesday. To call thos...
Tags: Finance, Health Care, Vertex, Vertex Pharmaceuticals, ABBV, Vertex Pharmaceuticals NASDAQ, VRTX, Keith Speights, GLPG, 49b5b2fa-6c99-11e7-a560-0050569d4be0


S&P, Nasdaq at records as Vertex rallies; IBM slips

NEW YORK (Reuters) - The Nasdaq Composite and the S&P 500 hit record highs on Wednesday, powered by technology stocks and a more than 20 percent jump in Vertex Pharmaceuticals, while gains on the Dow were capped by a sharp drop in IBM shares.
Tags: New York, Money, businessNews, Ibm, Reuters, Vertex, Vertex Pharmaceuticals


US stocks keep rising as health care companies lead the way

NEW YORK (AP) — U.S. stocks are rising Wednesday morning as gains in health care and media companies put major indexes on track to set more records. Drugmaker Vertex Pharmaceuticals is surging on positive results from potential treatments for cystic fibrosis. Morgan Stanley is rising after the investment bank’s trading desks had a good second […]
Tags: Business, New York, News, US, Morgan Stanley, Vertex Pharmaceuticals, Nation & World


Markets Right Now: US stocks open higher

NEW YORK (AP) — The latest on developments in financial markets (All times local): 9:35 a.m. Stocks are rising further in morning trading as health care companies, banks and consumer companies all gain ground. Vertex Pharmaceuticals surged 25 percent Wednesday after it reported positive results from studies of a cystic fibrosis drug. Most Read StoriesWhat […]
Tags: Business, New York, News, US, Vertex Pharmaceuticals, Nation & World


3 Reasons Why Gilead Sciences Shouldn't Buy Vertex Pharmaceuticals

The idea of a marriage between Gilead Sciences (NASDAQ: GILD) and Vertex Pharmaceuticals (NASDAQ: VRTX) has been repeatedly floated by analysts for the better part of the last two years. After all, a deal to buy Vertex would easily fall within Gilead's price range, and it likely would be accretive to earnings within two years. So it shouldn't come as a surprise that a handful of analysts revisited this idea yet again last week. Still, while there's little doubt that Gilead needs to do someth...
Tags: Finance, Health Care, Gilead, Vertex, Vertex Pharmaceuticals, Vertex Pharmaceuticals NASDAQ, Getty Images Continue, Gild, ALXN, Gilead Sciences NASDAQ, George Budwell, VRTX, BMRN, 02288888-5f8b-11e7-8709-0050569d4be0, Gilead Sciences Shouldn


Is Vertex Pharmaceuticals Running Out of Steam or Taking a Breather?

Vertex Pharmaceuticals (NASDAQ: VRTX) has enjoyed a remarkable run so far in 2017. Just last week, the biotech stock was up 81% year to date.There has been a lot of good news for the developer of cystic fibrosis (CF) drugs. However, over the past few days, Vertex stock has slipped somewhat. Is Vertex running out of steam or just taking a breather? Image source: Vertex Pharmaceuticals. https://www.vrtx.com/pipeline-medicines/independent-researchContinue reading [Author: [email protected] (K...
Tags: Finance, Health Care, Vertex, Vertex Pharmaceuticals, ABBV, Vertex Pharmaceuticals NASDAQ, VRTX, Keith Speights, GLPG, 4c1ec518-5c18-11e7-a698-0050569d4be0


​Vertex shareholders reject proposal on lobbying transparency

Shareholders of Vertex Pharmaceuticals have overwhelmingly rejected a proposal by religious groups that asked the Boston drugmaker to disclose more information about its lobbying activities. Vertex (Nasdaq: VRTX) said in a federal filing that nearly three-quarters of its shareholders had voted against the non-binding proposal during the company’s annual meeting on Thursday. Vertex opposed the measure, which urged it to disclose how much it spends on lobbying, including payments to trade groups…...
Tags: Boston, Vertex, Vertex Pharmaceuticals, VRTX, Vertex Nasdaq


Vertex shares soar in 2017, and the best may be yet to come

Vertex Pharmaceuticals has been the top-performing stock in the S&P 500 so far this year, and further gains could be on the horizon. Shares of Boston-based Vertex (Nasdaq: VRTX), which makes cystic fibrosis drugs, have increased around 70 percent since the beginning of the year. That marks the biggest gain of any company on the S&P 500 during that period. (That fact was pointed out by the Wall Street Journal on Wednesday.) The jump can be attributed in part to the company’s announcement in lat...
Tags: Boston, Wall Street Journal, Vertex, Vertex Pharmaceuticals, VRTX, Vertex Nasdaq